Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for smoking cessation in subjects with cardiovascular disease
2005-004411-29Phase 3Completed
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nicotine dependence comparing Varenicline with Placebo (2 arms). Primary endpoint: 4-week Continuous Quit Rate for Weeks 9-12. Started Nov 2005; status: completed.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2005-004411-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004411-29.